Flatley Discovery Lab to pursue development of FDL169 for cystic fibrosis treatment

US-based Flatley Discovery Lab plans to develop FDL169, an orally available small molecule, as a clinical candidate for the treatment of cystic fibrosis (CF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news